Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study

Drug Metabolism and Disposition - Tập 41 Số 4 - Trang 754-762 - 2013
Jens P. Bankstahl1,2,3,4,5,6, Marion Bankstahl1,2,3,4,5,6, Kerstin Römermann1,2,3,4,5,6, Thomas Wanek1,2,3,4,5,6, Johann Stanek1,2,3,4,5,6, Albert D. Windhorst1,2,3,4,5,6, Maren Fedrowitz1,2,3,4,5,6, Thomas Erker1,2,3,4,5,6, Markus Müller1,2,3,4,5,6, Wolfgang Löscher1,2,3,4,5,6, Oliver Langer1,2,3,4,5,6, Claudia Kuntner1,2,3,4,5,6
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (J.S., M.M., O.L.)
2Department of Medicinal Chemistry, University of Vienna, Vienna, Austria (T.E.)
3Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands (A.D.W.)
4Department of Nuclear Medicine, Preclinical Molecular Imaging, Hannover Medical School, Hannover, Germany (J.P.B.)
5Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, and Center for Systems Neuroscience, Hannover, Germany (J.P.B., M.B., K.R., M.F., W.L.)
6Health and Environment Department, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., J.S., O.L., C.K.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

Allen, 2003, Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein, Cancer Res, 63, 1339

10.4161/cbt.1.4.22

Archinal-Mattheis, 1995, Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein, Oncol Res, 7, 603

10.1124/jpet.106.102491

10.1016/j.neuropharm.2006.07.038

10.1523/JNEUROSCI.6616-10.2011

10.1016/j.bmc.2010.06.057

10.1124/jpet.105.099648

10.1016/S0304-3835(99)00182-2

10.1158/1078-0432.CCR-07-1335

10.1021/jm900940f

10.1016/j.bmc.2011.02.039

10.1002/ejoc.200700142

Hyafil, 1993, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res, 53, 4595

10.1021/cn100078a

10.1007/s12149-010-0373-y

10.1007/s11307-010-0313-1

10.1124/jpet.109.162321

10.1021/jm8013822

10.1007/s00259-009-1332-5

10.1124/mi.9.3.7

10.1007/s002800050515

10.2967/jnumed.108.056226

10.1124/dmd.111.044420

10.1038/nrn1728

10.2174/156802610792928095

10.2174/138161211797440212

10.1016/j.neuropharm.2008.08.032

10.2174/138920011798356980

Maliepaard, 2001, Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918, Clin Cancer Res, 7, 935

10.1038/sj.bjp.0702807

10.1172/JCI119784

Meier, 2006, Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity, Biophys J, 91, 2943, 10.1529/biophysj.106.089581

10.1002/(SICI)1097-0215(19960729)67:3<435::AID-IJC20>3.0.CO;2-5

Padowski, 2010, Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein, J Pharm Sci, 99, 3226, 10.1002/jps.22070

10.1016/j.bmc.2008.07.034

10.1158/0008-5472.CAN-03-3298

10.2174/187152010794473957

10.1093/jnci/90.15.1161

Thomas H and Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control: journal of the Moffitt Cancer Center 10:159–165.

10.1016/j.addr.2010.09.011

10.1007/s00259-011-1941-7

10.1038/jcbfm.2012.112

Thông tin
Thông tin xuất bản

Drug Metabolism and Disposition

Tập 41 Số 4

754-762

Thông tin tác giả